Answer
Fotivda is indicated for first-line treatment of adults with advanced renal cell carcinoma and for adults whose disease progressed after one prior cytokine therapy and who have not received VEGFR or mTOR pathway inhibitors.
Sources for this answer
- Fotivda 890mcg hard capsulesRecordati UK Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 13Document updated
Sources checked